BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15157043)

  • 1. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events.
    Rosenzweig MQ; Bender CM; Lucke JP; Yasko JM; Brufsky AM
    J Pain Symptom Manage; 2004 Feb; 27(2):185-90. PubMed ID: 15157043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy.
    Henry DH; Brooks BJ; Case DC; Fishkin E; Jacobson R; Keller AM; Kugler J; Moore J; Silver RT; Storniolo AM; Abels RI; Gordon DS; Nelson R; Larholt K; Bryant E; Rudnick S
    Cancer J Sci Am; 1995; 1(4):252-60. PubMed ID: 9166485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recombinant human erythropoietin in anemia associated with pediatric cancer: study of the identification of predictors of response].
    León Molinari P; Jiménez Monteagudo M; Barona Zamora P; Riol Diego M; Castro Paz L; Sierrasesúmaga Ariznavarreta L
    An Esp Pediatr; 1998 Jul; 49(1):17-22. PubMed ID: 9718761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recombinant erythropoietin (r-HuEPO) in the treatment of anemia in multiple myeloma].
    Spicka I; Haber J; Petruzelka L; Kolesková E; Sálková J; Straub J; Zounar R; Klener P
    Cas Lek Cesk; 1996 Jul; 135(14):450-3. PubMed ID: 8925545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin.
    Dunphy FR; Dunleavy TL; Harrison BR; Boyd JH; Varvares MA; Dunphy CH; Rodriguez JJ; McDonough EM; Minster JR; McGrady MD
    Cancer; 1997 Apr; 79(8):1623-8. PubMed ID: 9118049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer.
    Dusenbery KE; McGuire WA; Holt PJ; Carson LF; Fowler JM; Twiggs LB; Potish RA
    Int J Radiat Oncol Biol Phys; 1994 Jul; 29(5):1079-84. PubMed ID: 8083076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human erythropoietin for the treatment of anemia in patients with advanced cancer.
    Henry DH
    Semin Hematol; 1993 Oct; 30(4 Suppl 6):12-6. PubMed ID: 8153671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study.
    Lavey RS; Liu PY; Greer BE; Robinson WR; Chang PC; Wynn RB; Conrad ME; Jiang C; Markman M; Alberts DS
    Gynecol Oncol; 2004 Oct; 95(1):145-51. PubMed ID: 15385124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recombinant human erythropoietin in the treatment of anemic patients undergoing chemotherapy for cancer].
    Bösze P; Mayer A; Thurzó L; Kiss A; Rák K; Stumpf J
    Orv Hetil; 1995 Nov; 136(47):2567-72. PubMed ID: 8532322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
    Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
    Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
    Aapro M; Leonard RC; Barnadas A; Marangolo M; Untch M; Malamos N; Mayordomo J; Reichert D; Pedrini JL; Ukarma L; Scherhag A; Burger HU
    J Clin Oncol; 2008 Feb; 26(4):592-8. PubMed ID: 18235117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting anemia management in hemodialysis patients: a single-center experience.
    Spiegel DM; Gitlin M; Mayne T
    Hemodial Int; 2008 Jul; 12(3):336-41. PubMed ID: 18638090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.
    Wright JR; Ung YC; Julian JA; Pritchard KI; Whelan TJ; Smith C; Szechtman B; Roa W; Mulroy L; Rudinskas L; Gagnon B; Okawara GS; Levine MN
    J Clin Oncol; 2007 Mar; 25(9):1027-32. PubMed ID: 17312332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of symptomatic deep venous thrombosis with epoetin alfa or darbepoetin alfa treatment of anemia in patients with ovarian or primary peritoneal cancer.
    Westin SN; Skinner EN; Jonsson Funk M; Gehrig PM; Van Le L
    Gynecol Oncol; 2007 May; 105(2):414-7. PubMed ID: 17250880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies.
    Straus DJ; Testa MA; Sarokhan BJ; Czuczman MS; Tulpule A; Turner RR; Riggs SA
    Cancer; 2006 Oct; 107(8):1909-17. PubMed ID: 16977654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin (r-HuEPO) in the treatment of anemia of nodular sclerosis type Hodgkin's disease--a preliminary report.
    Wojtukiewicz MZ; Sawicki Z; Radziwon P
    Rocz Akad Med Bialymst; 2000; 45():145-9. PubMed ID: 11712426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.
    Witzig TE; Silberstein PT; Loprinzi CL; Sloan JA; Novotny PJ; Mailliard JA; Rowland KM; Alberts SR; Krook JE; Levitt R; Morton RF
    J Clin Oncol; 2005 Apr; 23(12):2606-17. PubMed ID: 15452187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.